18β-Glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis

Ocular Immunology and Inflammation

Volumn 19, Issue 3, 2011, Pages 180-185

  Cavone, Leonardo ^a   Muzzi, Mirko ^a   Mencucci, Rita ^a   Sparatore, Bianca ^b   Pedrazzi, Marco ^b   Moroni, Flavio ^a   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

blepharitis; conjunctivitis; glycyrrhetic acid; HMGB1; macrophages

Indexed keywords

ANTIBODY; CYCLOOXYGENASE 2; GLYCYRRHETINIC ACID; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; ANTIGEN BINDING; ARTICLE; BLEPHARITIS; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LACRIMAL FLUID; MACROPHAGE; MALE; PROTEIN EXPRESSION;

ADULT; ANTIBODIES; BLEPHARITIS; CELLS, CULTURED; CONJUNCTIVITIS; CYCLOOXYGENASE 2; ENZYME INDUCTION; FEMALE; GLYCYRRHETINIC ACID; HMGB1 PROTEIN; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; TEARS;

EID: 79957517361     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.538121     Document Type: Article

References (29)

1. Landsman D, Bustin M. A signature for the HMG-1 box DNA-binding proteins. Bioessays. 1993: 15: 539-546
2. Yu SS, et al. Interaction of non-histone chromosomal proteins HMG1 and HMG2 with DNA. Eur J Biochem. 1977: 78: 497-502 (Pubitemid 8173603)
3. Ellwood KB, et al. Mechanism for specificity by HMG-1 in enhanceosome assembly. Mol Cell Biol. 2000: 20: 4359-4370 (Pubitemid 30346630)
4. Allain FH, et al. Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structuraldeterminants for non-sequence- specific binding. EMBO J. 1999: 18: 2563-2579 (Pubitemid 29213287)
5. Verrijdt G, et al. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J. 2002: 361: 97-103 (Pubitemid 34171413)
6. Bianchi ME. HMGB1 loves company. J Leukoc Biol. 2009: 86: 573-576
7. Scaffidi P, et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002: 418: 191-195 (Pubitemid 34773774)
8. Bianchi ME. Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol. 2004: 14: 287-293 (Pubitemid 38798177)
9. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005: 5: 331-342 (Pubitemid 40516158)
10. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005: 17: 359-365 (Pubitemid 40848537)
11. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2006
12. Dumitriu IE, et al. HMGB1: guiding immunity from within. Trends Immunol. 2005: 26: 381-387 (Pubitemid 40835844)
13. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006: 17: 189-201 (Pubitemid 43949075)
14. Hoppe G, et al. Diurnal rhythm of the chromatin protein Hmgb1 in rat photoreceptors is under circadian regulation. J Comp Neurol. 2007: 501: 219-230 (Pubitemid 46233330)
15. Pachydaki SI, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2006: 82: 807-815 (Pubitemid 43170881)
16. Arimura N, et al. High-mobility group box 1 protein in endophthalmitis. Graef's Arch Clin Exp Ophtalmol. 2008: 246: 1053-1058
17. Arimura N, et al. Intraocular expression and release of highmobility group box 1 protein in retinal detachment. Laboratory Investigation. 2009: 89: 278-287
18. Mollica L, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007: 14: 431-441 (Pubitemid 46617319)
19. Pedrazzi M, et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol. 2007: 179: 8525-8532
20. Sitia G, et al. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol. 2007: 81: 100-107 (Pubitemid 46021258)
21. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007: 81: 1-5 (Pubitemid 46028489)
22. Gardella S, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002: 3: 995-1001 (Pubitemid 35256475)
23. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007: 220: 35-46 (Pubitemid 350045574)
24. Watanabe T, et al. High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2009: 50: 2283-2290
25. Ulloa L, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002: 99: 12351-12356
26. Killeen ME, et al. The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 2647 cells. J Pharmacol Exp Ther. 2006: 316: 1070-1079 (Pubitemid 43345280)
27. Sakamoto R, et al. Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro. Biol Pharm Bull. 2001: 24: 906-911 (Pubitemid 32750316)
28. van Rossum TG, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001: 96: 2432-2437 (Pubitemid 32769207)
29. Radi ZA, Render JA. The pathophysiologic role of cyclo-oxygenases in the eye. J Ocul Pharmacol Ther. 2008: 24: 141-151 (Pubitemid 351450473)